Mirza N B, Wamola I A, Estambale B A, Mbithi E, Poillet M
Department of Medical Microbiology, University of Nairobi, Kenya.
East Afr Med J. 1995 Mar;72(3):162-4.
Safety, tolerance and immunogenicity of the purified Vi polysaccharide vaccine (Typhim Vi) against typhoid fever was evaluated in primary school children aged 5-15 years. A total of 435 children were vaccinated, each with a single intramuscular injection in the left deltoid muscle. One hundred and ten children were randomly selected for blood samples on day 0 (pre vaccination) and day 30 (post vaccination). Vi antibodies studied by Radio immuno assay (RIA) on 97(88%) paired sera showed a seroconversion rate of 76.2% and seroprotection rate after vaccination was 74.2%, while 6.2% of children already had protective immunity before vaccination. The vaccine was well tolerated. Most commonly reported reactions were mild pain at site of injection (83%), and a few complained of mild swelling (4.6%), induration (1.1%), itching (1.1%) and headaches (1.4%). All reactions were of mild severity and disappeared within 24 to 48 hours.
在5至15岁的小学生中评估了纯化Vi多糖疫苗（伤寒Vi疫苗）预防伤寒热的安全性、耐受性和免疫原性。共有435名儿童接种疫苗，均在左三角肌进行单次肌肉注射。随机选择110名儿童在第0天（接种前）和第30天（接种后）采集血样。通过放射免疫分析（RIA）对97份（88%）配对血清进行的Vi抗体研究显示，血清转化率为76.2%，接种后血清保护率为74.2%，而6.2%的儿童在接种前已有保护性免疫力。该疫苗耐受性良好。最常报告的反应是注射部位轻度疼痛（83%），少数人抱怨有轻度肿胀（4.6%）、硬结（1.1%）、瘙痒（1.1%）和头痛（1.4%）。所有反应均为轻度，在24至48小时内消失。
